1/3. Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study.Tardive akathisia (TA) is a well-documented side-effect of neuroleptic treatment. The underlying mechanism is poorly understood, and treatment is unsatisfactory. In this case report, TA that occurred in the course of a tardive dyskinesia (TD) was successfully treated with the monoamine-oxidase-A inhibitor moclobemide. With respect to the mechanism of action, it may be hypothesized that dopaminergic supersensitivity in the mesocortical region is counteracted by enhanced inhibition of primarily noradrenergic neurotransmission.- - - - - - - - - - ranking = 1keywords = neurotransmission (Clic here for more details about this article) |
2/3. fluoxetine-induced akathisia: clinical and theoretical implications.Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia. The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia. Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder. Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both. The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced "jitteriness" may be identical.- - - - - - - - - - ranking = 1keywords = neurotransmission (Clic here for more details about this article) |
3/3. lithium-induced akathisia responds to low-dose mianserin: case report.A case of acute akathisia induced by lithium treatment is described. Since lithium administration leads to activation of serotonergic neurotransmission, the 5-HT2A/2C and 5-HT3 antagonist mianserin was added as a possible anti-akathitic agent. mianserin treatment (15 mg/day at 21.00 h) resulted in amelioration of the lithium-induced akathisia.- - - - - - - - - - ranking = 1keywords = neurotransmission (Clic here for more details about this article) |